NASDAQ · AUPH
Aurinia Pharmaceuticals Inc.
$15.35 +$0.11 (+0.72%) 1D After hoursKey Metrics
$1.96B
Market cap
6.57×
P/E · TTM
$298.30M
Revenue · TTM
$298.21M
Net income
EPS · TTM
$2.08
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.74
EBITDA · TTM
$153.14M
Gross margin
—
Snapshot
Market cap$1.96B
Enterprise value—
Shares outstanding128.6M
52-wk range$8.80 – $19.25
Avg volume · 20D2.4M
Net cash
—
Book value / share$3.96
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Aurinia Pharmaceuticals Inc.
IPO dateOct 21, 2009
Employees128
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E6.57
P/S6.57
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №$13.63
Profitability
Gross
—
Operating
44.8%
Net
100.0%
FCF
—
ROE / ROIC
63.1% · 56.6%
Financial Health
Current ratio5.55
Quick ratio5.01
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$393.69M
Cash Flow · TTM
Operating CF
$166.92M
Capex
—
Free cash flow
—
Buybacks
$87.40M
Dividends paid
—
Shareholder yield
4.5%
Piotroski F-Score
4 / 9
Middling fundamentals · 4 of 9 signals passing
Altman Z-Score
8.0
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
$13.63 vs $15.35
Trades 1.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings